
2 Gajapati men die during running test for home guard job
Berhampur: Two men died and six others had to be hospitalised during a physical test for the recruitment of home guards in Paralakhemundi, Gajapati district, on Thursday.
The deceased were identified as Sulant Mishal (24), a resident of Parisal village, and Deepak Padalu (27), a native of Narayanpur village.
Tired of too many ads? go ad free now
This is the fifth casualty in the state during physical tests for govt jobs in the past two months.
Police said Mishal, a final year Plus III student, had completed a 2-kilometre run within 10 minutes and qualified for the next round of selection. However, minutes after finishing the test, he complained of uneasiness. He was rushed to the district headquarters hospital (DHH), where doctors declared him dead. Mishal's father had died some years back.
He was living with his mother, who works as a labourer.
"An autopsy was conducted, and the procedure was videographed in the presence of a magistrate. The cause of death will be known only after receiving the postmortem report," said Gajapati SP Jatindra Kumar Panda. Police suspect Mishal may have had some past ailments, which got aggravated during the running exercise.
Deepak, who had become unconscious after taking part in the running test, died at MKCG Medical College and Hospital, Berhampur.
Deepak and six other candidates who fell ill during the test were admitted to the DHH. Deepak was later shifted to Berhampur after his condition deteriorated in the afternoon. He died in the evening.
Though the exact cause of the death would be ascertained after postmortem, doctors suspected he died of heart attack. All those hospitalised complained of muscle cramps and body pain. Of the rest six, three were discharged and three were still in hospital.
Tired of too many ads? go ad free now
Chief minister Mohan Charan Majhi announced an ex gratia of Rs 4 lakh from the CM's Relief Fund to the next of kin of the deceased.
The recruitment test was part of a drive to fill 144 home guard posts in Gajapati. Over 1,700 candidates, including 300 women, participated in the physical test on Thursday. The female candidates ran in the first batch at 6.30 am, followed by male candidates in groups of 300.
"We had advised candidates not to take part in the test if they felt unwell.
Advance notices had been issued on this matter," said SP Panda.
On March 5, two engineering graduates — Byomkesh Naik of Keonjhar and Prabin Kumar Panda of Sundargarh — died during a 25-kilometre walking test for forest department recruitment. Another home guard aspirant collapsed and died during a running test in Deogarh on March 27.
Berhampur: Two men died and six others had to be hospitalised during a physical test for the recruitment of home guards in Paralakhemundi, Gajapati district, on Thursday.
The deceased were identified as Sulant Mishal (24), a resident of Parisal village, and Deepak Padalu (27), a native of Narayanpur village. This is the fifth casualty in the state during physical tests for govt jobs in the past two months.
Police said Mishal, a final year Plus III student, had completed a 2-kilometre run within 10 minutes and qualified for the next round of selection. However, minutes after finishing the test, he complained of uneasiness.
He was rushed to the district headquarters hospital (DHH), where doctors declared him dead. Mishal's father had died some years back. He was living with his mother, who works as a labourer.
"An autopsy was conducted, and the procedure was videographed in the presence of a magistrate. The cause of death will be known only after receiving the postmortem report," said Gajapati SP Jatindra Kumar Panda. Police suspect Mishal may have had some past ailments, which got aggravated during the running exercise.
Deepak, who had become unconscious after taking part in the running test, died at MKCG Medical College and Hospital, Berhampur. Deepak and six other candidates who fell ill during the test were admitted to the DHH. Deepak was later shifted to Berhampur after his condition deteriorated in the afternoon. He died in the evening.
Though the exact cause of the death would be ascertained after postmortem, doctors suspected he died of heart attack.
All those hospitalised complained of muscle cramps and body pain. Of the rest six, three were discharged and three were still in hospital.
Chief minister Mohan Charan Majhi announced an ex gratia of Rs 4 lakh from the CM's Relief Fund to the next of kin of the deceased.
The recruitment test was part of a drive to fill 144 home guard posts in Gajapati. Over 1,700 candidates, including 300 women, participated in the physical test on Thursday.
The female candidates ran in the first batch at 6.30 am, followed by male candidates in groups of 300.
"We had advised candidates not to take part in the test if they felt unwell. Advance notices had been issued on this matter," said SP Panda.
On March 5, two engineering graduates — Byomkesh Naik of Keonjhar and Prabin Kumar Panda of Sundargarh — died during a 25-kilometre walking test for forest department recruitment. Another home guard aspirant collapsed and died during a running test in Deogarh on March 27.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
38 minutes ago
- Time of India
Tamil Nadu intensifies tobacco ban near schools, seizes 4.1 lakh kg, imposes INR 39 cr in fines
CHENNAI: The Tamil Nadu government has stepped up enforcement against the sale and distribution of tobacco products near schools and colleges, as part of its ongoing public health efforts. In an official release, the government said it had instructed the Tamil Nadu Police, Food Safety Department, and local bodies to undertake focused enforcement drives to ensure strict adherence to anti-tobacco laws in areas surrounding educational institutions. To facilitate these efforts, 391 joint inspection teams -- comprising officials from the Police, Food Safety and Standards Department, and the Municipal Administration and Water Supply Department -- have been formed to conduct routine checks near schools and colleges across the state. The manufacture, storage, transport, distribution, and sale of oral tobacco products such as gutkha, pan masala, Cool Lip, and other forms of chewable tobacco remain banned in Tamil Nadu under a Government Order issued under Section 30(2)(a) of the Food Safety and Standards Act, 2006. The state has been running an extensive enforcement campaign since November 2023. According to the government, the Food Safety Department has inspected over 5.2 lakh shops and transport vehicles during this period. Of these, 13,642 shops were found selling prohibited tobacco products. Authorities have seized 1.8 lakh kilograms of banned tobacco, including 5,258 kg of the product Cool Lip. A total fine of Rs 39.14 crore has been imposed on violators by the Food Safety and Standards Department. In a parallel effort, the Tamil Nadu Police have registered 43,167 cases and confiscated over 4.1 lakh kg of banned tobacco items. Reaffirming its stance, the government said: "The Tamil Nadu government reiterates its unwavering commitment to protecting public health, particularly children and young adults. On this World No Tobacco Day, the state calls on all citizens to support and cooperate with these enforcement efforts and to work towards a tobacco-free environment around educational institutions." The initiative underscores the state's continued focus on reducing tobacco use and ensuring a safe and healthy atmosphere for students and youth. Ready to empower your child for the AI era? Join our program now! Hurry, only a few seats left.


The Print
42 minutes ago
- The Print
Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market
Insulin is a hormone that helps move glucose (sugar) from the bloodstream into cells to stop it from building up in the bloodstream. Patients with type 1 diabetes or advanced type 2 diabetes need to administer insulin, typically multiple times a day, in order to keep their blood sugar in a healthy range. Now, with a number of Indian drugmakers foraying into the insulin market in the country once dominated by multinational drugmakers—Big Pharma, its cost is expected to dip further. New Delhi: Insulin, a lifeline for nearly all patients with type 1 diabetes and nearly 10 percent of those with type 2 diabetes, is available in India at an average cost of Rs 133 per vial—among the cheapest in the world. With the country seeing a near explosion of diabetes, the size of India's insulin market stood at an estimated Rs 4,404 crore in April this year, according to Pharmatrac, a market research company that tracks the Indian drug market. Its April report, the latest, which ThePrint has seen, said, 'Indian players are making a steady entry in the Insulins market that was once dominated by MNCs'. Four Indian companies have launched various insulin brands in India over the last two years in the segment where multinationals such as Novo Nordisk, Eli Lilly and Company and Sanofi have ruled the roost, according to Pharmatrac statistics. It added that with innovator companies like Eli Lilly and Novo Nordisk increasingly focusing on the anti-obesity segment (Mounjaro, Ozempic and Wegovy), it opens 'doors of opportunity for the Indian players' to expand their footprint. According to data from the Pharmatrac report, of over 90 insulin brands available in the Indian market, 14 have a collective market share of more than 80 percent. Of these, 11 are owned by either Novo Nordisk, which has a tie-up with Abbott for marketing them in India, or Sanofi, while one brand, Huminsulin by US-based pharma giant Eli Lilly, was sold to Indian drugmaker Lupin last year. The two best-selling insulin brands in the country include Mixtard and Ryzodeg, both by Danish drugmaker Novo Nordisk. Mixtard alone has a market of over Rs 800 crore in India. The only Indian company, which has two brands among the top-selling 14 insulin brands, is Ahmedabad-based Eris Lifesciences. Indian companies that have entered the segment since 2023 include USV, Anthem Biopharma, Cadila and Mankind. Additionally, Cipla, following a strategic tie-up with Eli Lilly, launched its insulin drug, Lyumjev, in India in October 2023. Pharmatrac statistics also showed that Indian companies, which include Eris Lifesciences, Cipla and Mankind, apart from Lupin, sold insulin worth Rs 1,088 crore between April 2024 and April 2025—24.7 percent of the total insulin market. However, as of now, a large number of diabetics in need of insulin still cannot access or afford the new generation versions that are more convenient to use, and most new brands being launched in India have yet to address this issue. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Further price crashes expected In 2023, the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation estimated that nearly 101 million people in India had diabetes. It is suggested that while the majority with the condition have type 2 diabetes, the number of those with type 1 is also estimated to be around 9 lakh, and this includes a large number of those under 18 years of age. Type 1 diabetes, say experts, is characterised by complete loss of the insulin-producing beta cells due to an autoimmune disease or idiopathic (unknown) reasons. Type 2 diabetes, also called diabetes mellitus, on the other hand, is mainly triggered by insulin resistance or the body's inability to respond to insulin, often combined with relatively reduced insulin secretion and is linked with lifestyle issues such as poor dietary habits and lack of physical activity. Nearly 10 percent of patients with type 2 diabetes, mainly those in the advanced or severe stage of the condition, require insulin, but for all patients with type 1 diabetes, insulin is mandatory, mostly 3-4 times a day Type 1 diabetes is growing at a rate of 6.7 percent annually in India, compared to 4.4 percent for type 2 diabetes, the latest Pharmatrac report noted. Diabetologist and researcher Dr V. Mohan underlined that the exact reason why the number of people with type 1 diabetes is growing may not be properly understood, but it could also be due to better awareness about the condition and quicker diagnosis. 'Earlier, many with type 1 diabetes used to die within years of disease onset as they did not get insulin on time, but now they are living longer, and those with type 2 diabetes, after living with the condition for years, typically need insulin,' he said. This is why, the clinician-researcher said, the insulin segment is growing rapidly in the country. Adding, 'More competition is always good because that will help to keep up the quality of the product and also bring down the price of the insulin.' Industry insiders said the trend of Indian firms entering the segment was mainly prompted by expiration of patents on key insulin analogues and rapid global adoption of GLP-1 analogues like semaglutide and tirzepatide, used for diabetes and obesity management 'With diabetes now recognised as a national health priority, domestic companies are investing in biosimilar innovation, scaling production capabilities, and forming strategic collaborations to secure insulin supply for the domestic market,' said Saransh Chaudhary, president (global critical care) of research-driven pharma company Venus Remedies. Innovative therapy, devices for diabetics Till the 70s the insulin used by those in need was derived from animals like pigs and cows, while the 80s saw the advent of human insulin, a type of synthetic insulin made in a laboratory that mimics the insulin our body makes. Over the last 15-20 years, insulin analogues, which are more convenient and quicker to act, have been in use in developed countries. This type of medicine is made in the same way as human insulin but is genetically altered to change the way it acts in the body. More expensive than human insulin, insulin analogues have a different chemical structure and are designed to act more rapidly, within 5-10 minutes of administration and for a longer time of up to 40 hours, ensuring ease in diabetes care. These often come in specifically designed devices such as pre-filled pens that are simply administered through a click, instead of most human insulins in vials that have to be administered as an injection. However, as these formulations are not part of the National List of Essential Medicines (NLEM) and are costlier—typically costing Rs 10,000-15,000 per month—most Indian diabetics in need of insulin therapy cannot afford them. As of now, only some basic formulations of insulin are on the NLEM, whose upper price ceilings are fixed by the government. Once protected by patent, as some of them are now off-patent, their biosimilar versions—just like generics in case of small molecule drugs—have now hit the Indian market, and it could change the affordability issue, underlined Dr Manisha Arora, director, internal Medicine at the CK Birla Hospital. 'The entry of multiple pharmaceutical companies into this space reflects the segment's growth potential and the opportunity to enhance treatment outcomes through competitive pricing and technological advancements,' she said. Increased competition could spur further innovation, improve patient-centric delivery systems, and contribute to a more sustainable and equitable diabetes care ecosystem, Arora added. (Edited by Sanya Mathur) Also Read: ICMR-led consortium seeks health tax on fat, sugar & salt-rich foods to cut adolescent obesity burden


Hans India
2 hours ago
- Hans India
Shaheen Group secures 500 MBBS seats for Indian students in Tajikistan
Hyderabad: As hundreds of students fail to secure MBBS seats through merit or management quotas, Shaheen Group of Institutions has signed a Memorandum of Understanding (MoU) with the Medical Social Institute of Tajikistan, under which 500 students will be able to pursue MBBS degrees at the institute. As part of the collaboration, the Ambassador of Tajikistan to India, along with the Cultural Ambassador and other diplomatic representatives, visited the Shaheen Campus. Dr Zainab, the Tajikistan coordinator, assured that full security is provided to international students there. Dr Abdul Qadeer, Chairman of the Shaheen Group of Institutions, explained that this agreement offers such students a chance to fulfill their dream of becoming doctors. He further stated that students can complete the entire six-year MBBS course, including hostel accommodation and Indian food, for just Rs 32 lakh. Dr Qadeer shared that the course fee can be paid in easy installments. The registration fee is Rs 49,500, and registrations will remain open until the end of June. The Rs 32 lakh package also includes insurance coverage. In a significant move, Shaheen Group and its medical partners will provide FMGE (Foreign Medical Graduate Examination) coaching from the first day of the MBBS course. This ensures that students are well-prepared to obtain a license for medical practice after graduation. For more information, visit: